Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis
Saved in:
| Published in: | Health Economics Review |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1871650362361905152 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Health Economics Review |
| description | |
| discipline_display | Economic Sciences General |
| discipline_facet | Economic Sciences General |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:106355 |
| institution | FRELIP |
| journal_source_facet | Health Economics Review |
| last_indexed | 2026-07-25T02:01:18.564Z |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis Economic Sciences General General Economic Sciences General |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Economic Sciences General General Economic Sciences General Economic Sciences General General Economic Sciences General |
| subject_facet | Economic Sciences General General Economic Sciences General |
| title | Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis |
| title_auth | Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis |
| title_full | Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis |
| title_fullStr | Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis |
| title_full_unstemmed | Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis |
| title_short | Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with PD-L1-positive: a cost-effectiveness analysis |
| title_sort | sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer with pd-l1-positive: a cost-effectiveness analysis |
| topic | Economic Sciences General General Economic Sciences General |
| url | https://link.springer.com/article/10.1186/s13561-026-00824-x |